[Diagnosis and medical treatment of pulmonary arterial hypertension].
The idiopathic pulmonal arterial hypertension is characterized by a chronic proliferative conversion of the pulmonary arterial vessels leading to an increase of pulmonary vascular resistance and thus resulting in right heart failure and increase mortality rate. With growing advances in understanding of the underlying pathophysiological mechanisms and the development of modern medical treatment strategies, there is a significant improvement of the overall survival rate and quality-of life. In this review we will give an overview about the current knowledge of etiology, diagnosis and management of idiopathic pulmonal arterial hypertension.
Akin
I
I
Klinikum I, Abteilung für Kardiologie, Pulmonologie, internistische Intensivmedizin, Universität Rostock.
Ince
H
H
Kische
S
S
Schneider
H
H
Ortak
J
J
Rehders
T C
TC
Nienaber
C A
CA
Chatterjee
T
T
D000328:Adult; D000465:Algorithms; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004452:Echocardiography; D015150:Echocardiography, Doppler; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D011453:Prostaglandins / Q000627:therapeutic use; D011788:Quality of Life; D013902:Radiography, Thoracic; D012737:Sex Factors; D014057:Tomography, X-Ray Computed
D002121:Calcium Channel Blockers; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins